Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.72 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.70 -0.02 (-1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Fortress Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 81 | 178 | 306 | 233 | 137 |
Receivables | 15 | 28 | 24 | 20 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 14 | 10 | 1 | 1 |
Other Current Assets | 11 | 10 | 7 | 7 | 4 |
Total Current Assets | 117 | 230 | 346 | 262 | 156 |
Net Property & Equipment | 7 | 13 | 15 | 12 | 12 |
Investments & Advances | 0 | 0 | 0 | 18 | 11 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 20 | 27 | 13 | 15 | 7 |
Deposits & Other Assets | 7 | 4 | 3 | 3 | 18 |
Total Assets | 168 | 294 | 397 | 329 | 226 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 3 | 7 | 5 | 5 | 7 |
Accounts Payable | 74 | 97 | 91 | 41 | 35 |
Current Portion Long-Term Debt | 0 | 3 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1 | 1 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 17 | 3 | 0 | 1 |
Total Current Liabilities | 85 | 128 | 101 | 48 | 46 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 61 | 93 | 47 | 59 | 77 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 2 | 2 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 166 | 244 | 171 | 132 | 154 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 1 |
Capital Surplus | 717 | 676 | 656 | 583 | 462 |
Retained Earnings | -695 | -634 | -547 | -483 | -436 |
Other Equity | -21 | 8 | 117 | 97 | 46 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2 | 50 | 226 | 197 | 73 |
Total Liabilities & Shareholder's Equity | 168 | 294 | 397 | 329 | 226 |
Total Common Equity | 2 | 50 | 226 | 197 | 73 |
Shares Outstanding | 15.00 | 7.30 | 6.60 | 6.20 | 4.70 |
Book Value Per Share | 0.11 | 6.85 | 34.22 | 31.77 | 15.43 |
Fiscal Year End for Fortress Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 81 | 72 | 87 | 152 |
Receivables | NA | 15 | 8 | 17 | 28 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 10 | 11 | 12 | 13 |
Other Current Assets | NA | 11 | 6 | 12 | 8 |
Total Current Assets | NA | 117 | 98 | 128 | 202 |
Net Property & Equipment | NA | 7 | 7 | 7 | 12 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 20 | 21 | 22 | 26 |
Deposits & Other Assets | NA | 7 | 7 | 6 | 3 |
Total Assets | NA | 168 | 151 | 181 | 264 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 3 | 3 | 2 | 2 |
Accounts Payable | NA | 74 | 81 | 99 | 105 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 3 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 1 | 0 | 0 | 1 |
Other Current Liabilities | NA | 5 | 10 | 25 | 16 |
Total Current Liabilities | NA | 85 | 97 | 129 | 129 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 61 | 46 | 47 | 91 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 2 | 2 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 166 | 164 | 197 | 244 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 717 | 702 | 699 | 693 |
Retained Earnings | NA | -695 | -686 | -681 | -656 |
Other Equity | NA | -21 | -30 | -34 | -18 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 2 | -13 | -16 | 20 |
Total Liabilities & Shareholder's Equity | NA | 168 | 151 | 181 | 264 |
Total Common Equity | 0 | 2 | -13 | -16 | 20 |
Shares Outstanding | 19.20 | 15.00 | 8.80 | 8.90 | 8.60 |
Book Value Per Share | 0.00 | 0.11 | -1.50 | -1.79 | 2.30 |